Monthly Archives: April 2018

Healthy.io Brings Smartphone Urine Tests to U.S. Homes

The Israel-based startup partnered with the American National Kidney Foundation and Pennsylvania-based Geisinger Health System to offer its testing kits to U.S. patients Lilach Baumer | 19:26 15.04.18 The American National Kidney Foundation and Pennsylvania-based Geisinger Health System have partnered with Israel-based startup Healthy.io to enable smartphone-based urine tests at home. On Monday, the three will [...]

By |2018-11-20T09:30:47+00:00April 16th, 2018|Blog|Comments Off on Healthy.io Brings Smartphone Urine Tests to U.S. Homes

Mylan buys rights to Israel-developed Multiple Sclerosis treatment

MS drug developed by Mapi Pharma requires a once-monthly injection instead of 3 times a week By TOI STAFF 11 April 2018, 12:19 am | Times New Israel Mylan already sells a generic version of Teva Pharmaceuticals’ widely-used MS treatment, Copaxone. But, if GA Depot successfully completes its Phase III clinical trials, it will be formidable competition [...]

By |2018-11-20T09:30:55+00:00April 12th, 2018|Blog|Comments Off on Mylan buys rights to Israel-developed Multiple Sclerosis treatment

Medtronic Buys Medical Visualization Company Visionsense for $65 Million

The medical device developer intends to integrate Israel-based Visionsense's operations into its own activities Meir Orbach | 10:16 10.04.18 | Calcalistech Medical device maker Medtronic PLC is buying Israel-based medical visualization company Visionsense Ltd. for $65 million, two people familiar with the matter told Calcalist on condition of anonymity. Visionsense will receive an upfront payment of [...]

By |2018-11-20T09:28:13+00:00April 12th, 2018|Blog|Comments Off on Medtronic Buys Medical Visualization Company Visionsense for $65 Million

Israeli Startup Ayala Taking BMS Cancer Drug Into Phase II With $17m Financing

EMERGING ISRAELI BIOPHARMA FLIES FLAG FOR EX-BMS CANCER THERAPY by Phil Taylor | Apr 10, 2018 9:57am | FierceBiotech Israeli biotech Ayala Pharmaceuticals, founded last year as a development vehicle for two of Bristol-Myers Squibb’s cancer candidates, has raised $17 million in a series A financing. The new company licensed rights to BMS’s gamma secretase inhibitor BMS-906024 in December, [...]

By |2018-11-20T09:52:18+00:00April 11th, 2018|Blog|Comments Off on Israeli Startup Ayala Taking BMS Cancer Drug Into Phase II With $17m Financing

Israel On Quest For Digital Health Domination

10 Apr 2018 | MEDTECH NEWS by Catherine Longworth Israel has set its sights on becoming a global leader in digital health, boosted by the government's new five-year plan to invest nearly $300m to drive innovation in this space. Israel is on a mission. The self-dubbed "Start-Up Nation" has proclaimed its ambition to become the world's [...]

By |2018-11-20T09:52:27+00:00April 11th, 2018|PR|Comments Off on Israel On Quest For Digital Health Domination

New VC fund to set sights on Israeli tech for eye diseases

Dr. Barak Azmon, an ophthalmologist and serial entrepreneur, is convinced Israel can become a 'meaningful player' in vision-related developments By SHOSHANNA SOLOMON| April 2018, 12:31 pm | Times of Israel Dr. Barak Azmon, an ophthalmologist and serial entrepreneur, is convinced Israel can become a “meaningful player” in technologies relating to eyesight. He and his partners [...]

By |2018-11-20T09:52:52+00:00April 9th, 2018|PR|Comments Off on New VC fund to set sights on Israeli tech for eye diseases

MIXiii-Biomed 2018 – Registration and program online

MIXiii-Biomed 2018 – Registration and program online MIXiii-Biomed 2018 is fast approaching. This prestigious conference and exhibition is once again ready to launch start-ups into the international arena and to help thousands of delegates connect and establish strong networking possibilities. REGISTER NOW Use this opportunity to participate and become a key player in the [...]

By |2018-04-09T14:44:26+00:00April 5th, 2018|News|Comments Off on MIXiii-Biomed 2018 – Registration and program online

Arie Belldegrun raises $300M, grabs Pfizer’s allogeneic CAR-T portfolio and launches a groundbreaking drive to commercialization

Dr. Arie Belldegrun, formerly Kite Pharma’s CEO, and Executive Chairman of Allogene Therapeutics, will be delivering the opening plenary talk at MIXiii-BIOMED conference, May 15-17, Tel Aviv. by john carroll — on April 3, 2018 08:00 AM EDT You need a license to cut-and-paste this copyrighted news content. Use this link to purchase your paid subscription ($200/year for individuals and [...]

By |2018-11-20T09:53:29+00:00April 4th, 2018|PR|Comments Off on Arie Belldegrun raises $300M, grabs Pfizer’s allogeneic CAR-T portfolio and launches a groundbreaking drive to commercialization

MIXiii-BIOMED 2018: Introducing the Best of Israel’s Life Science Innovations

Israel's 17th national life science and technology week to be held on May 15-17, 2018 at the David InterContinental Hotel in Tel Aviv NEWS PROVIDED BY MIXiii-BIOMED 07:30 ET | TEL AVIV, Israel, April 3, 2018 /PRNewswire/ The 17th annual MIXiii-BIOMED 2018, the premier international life science conference in Israel, will take place between May 15-17, 2018, at the David InterContinental Hotel in Tel [...]

By |2018-11-20T09:54:45+00:00April 3rd, 2018|PR|Comments Off on MIXiii-BIOMED 2018: Introducing the Best of Israel’s Life Science Innovations

MedImmune to Develop Compugen Immuno-Oncology Antibodies

April 2, 2018 | GEN News Highlights AstraZeneca’s #MedImmune subsidiary has agreed to exclusively license and develop #bispecific and multispecific #immuno-oncology antibody products from Compugen’s pipeline, through a collaboration that #Compugen said today could generate for it up to $210 million-plus. Compugen said it will grant MedImmune an exclusive license to develop bispecific and multispecific antibody products [...]

By |2018-11-20T09:55:08+00:00April 3rd, 2018|Blog|Comments Off on MedImmune to Develop Compugen Immuno-Oncology Antibodies